XML 37 R27.htm IDEA: XBRL DOCUMENT v3.23.1

Note 2 - Summary of Significant Accounting Policies (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Schedule of Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Table Text Block]

		March 31,				December 31,
		2023				2022
Cash and cash equivalents		$	3,746			$	5,362
Restricted cash included in other assets			476				484
Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows		$	4,222			$	5,846

Schedules of Concentration of Risk, by Product [Table Text Block]

		For the three Months Ended March 31,
		2023				2022
Avenova Spray		$	1,937			$	1,839
DERMAdoctor			785				1,043
NeutroPhase			—				148
Other products			395				237
Total product revenue, net			3,117				3,267
Other revenue, net			7				6
Total sales, net		$	3,124			$	3,273

Schedules of Concentration of Risk, by Risk Factor [Table Text Block]

		March 31,				December 31,
Major distribution partner		2023				2022
Avenova Spray Pharmacy Distributor A			35	%			30	%
Major U.S. Retailer A			15	%			*	%
Major U.S. Retailer B			12	%			*	%
Major U.S. Retailer C			*	%			15	%
Avenova Spray Pharmacy Distributor B			*	%			11	%

Schedule of Error Corrections and Prior Period Adjustments [Table Text Block]

		For the Three Months Ended March 31, 2022
		As Previously Reported				Selling Commissions				Fulfillment Fees				As Revised
Sales
Product revenue, net		$	2,623			$	298			$	346			$	3,267
Product cost of goods sold
Product cost of goods sold			1,113				-				346				1,459
Operating expenses
Sales and marketing			1,687				298				-				1,985
Net loss			(111	)			-				-				(111	)
Net loss per share attributable to common stockholders (basic and diluted)			(0.08	)			-				-				(0.08	)

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

		Three Months Ended March 31,
Numerator		2023				2022
Net loss		$	(1,739	)		$	(111	)
Denominator
Weighted average shares of common stock outstanding (basic and diluted)			2,035				1,431
Net loss per share attributable to common stockholders (basic and diluted)		$	(0.85	)		$	(0.08	)

Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]

		Three Months Ended March 31,
		2023				2022
Stock options			121				126
Stock warrants			2,306				1,274
			2,427				1,400

X

- Definition

Tabular disclosure of the components of cash, cash equivalents, restricted cash and restricted cash equivalents.

+ References

No definition available.

+ Details

Name:	nby_ScheduleOfCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsTableTextBlock
Namespace Prefix:	nby_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the concentration of risk by product type.

+ References

No definition available.

+ Details

Name:	nby_SchedulesOfConcentrationOfRiskByProductTableTextBlock
Namespace Prefix:	nby_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482662/260-10-50-1

+ Details

Name:	us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of prior period adjustments to previously issued financial statements including (1) the effect of the correction on each financial statement line item and any per-share amounts affected for each prior period presented (2) the cumulative effect of the change on retained earnings or other appropriate components of equity or net assets in the statement of financial position, as of the beginning of the earliest period presented, and (3) the effect of the prior period adjustments (both gross and net of applicable income tax) on the net income of each prior period presented in the entity's annual report for the year in which the adjustments are made.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-7

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

+ Details

Name:	us-gaap_ScheduleOfErrorCorrectionsAndPriorPeriodAdjustmentsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-21

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 825
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-20

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-18

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 20
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-20

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 16
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-16

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 275
-SubTopic 10
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482861/275-10-50-21

+ Details

Name:	us-gaap_SchedulesOfConcentrationOfRiskByRiskFactorTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_TableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration